Back to today’s briefing

Story perspectives

Merck Acquires SpringWorks for $3.9 Billion, Boosts Oncology

4/28/2025

23 3

Summary

Story summary

Merck KGaA is set to make waves in the biotech world with its $3.9 billion acquisition of SpringWorks Therapeutics, paying $47 per share. This strategic move not only bolsters Merck's oncology portfolio but also solidifies its foothold in the U.S. market, promising immediate revenue contributions upon completion in late 2025.

1 of 1

Story summary

Merck KGaA is set to make waves in the biotech world with its $3.9 billion acquisition of SpringWorks Therapeutics, paying $47 per share. This strategic move not only bolsters Merck's oncology portfolio but also solidifies its foothold in the U.S. market, promising immediate revenue contributions upon completion in late 2025.